Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Corporate Overview
Overview
Management Team
Board of Directors
Social Responsibility
NPC Blog
Presentations
Code of Ethics
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Board of Directors

Rik J. Deitsch

Rik J. Deitsch
Chairman and Chief Executive Officer
Nutra Pharma Corporation

Rik J. Deitsch has been the President, Chief Executive Officer and a Director of the Company since November 7, 2002. From February 1998 through November 2002, Mr. Deitsch served as the President of NDA Consulting Inc., a biotechnology research group that provided consulting services to the pharmaceutical industry. NDA Consulting specialized in the research of peptides derived from Cone Snail venom, Cobra venom and Gila Monster venom. Mr. Deitsch holds both a B.S. in Chemistry and an M.S. in Biochemistry from Florida Atlantic University and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic . Mr. Deitsch is an adjunct professor and teaches several courses for Florida Atlantic University's College of Business and Continuing Education Department.

   
   
Harold H. Rumph

Harold H. Rumph
Interim President
ReceptoPharm, Inc.

Harold H. Rumph has been a Director of the Company since March of 2003 and brings with him a career devoted to technical sales and marketing. From 1988 to 2003 he was founder and owner of a high tech business providing computerized scheduling services to the construction industry. From 1986 to 1988, Mr. Rumph was Director of Sales and Marketing for JE Research, Inc. From 1980 to 1986 he was a founder, President, and Director of Biogenix, Inc. This company was involved in the development, manufacturing, and marketing of in-hospital bedside and ambulatory Patient Monitoring Systems. Biogenix was also involved with research and development of antiviral peptides from cobra venoms, including clinical trials under FDA-issued Investigational New Drug applications. Prior to the above Mr. Rumph led sales teams and was responsible for marketing at Harris Communications, Harris Computers, Memorex Corporation, Xerox Corporation, Cincinnati Milacron, Amdahl Corporation, RCA Computers, and IBM. Mr. Rumph received his BS degree from the United States Naval Academy.

   
   
Dr. Stewart Lonky, MD

Dr. Stewart Lonky, MD
Director

Dr. Lonky is board certified in internal medicine, pulmonary and critical care medicine. As a National Institutes of Health post doctoral fellow and faculty member at the University of California, San Diego, he spearheaded a research team studying the cellular and biochemical mechanisms of lung injury. He has published over a dozen articles in the peer-reviewed literature in this field. His practice involves the evaluation and treatment of patients with toxic exposures as well as patients with lung disease, and he has co-authored the book Invisible Killers, The truth about environmental genocide.

From 1990-2006 he served as Chief Medical Officer of a medical device company that developed diagnostic products for the early diagnosis of cervical and oral cancer. In that role, his duties included the direction of clinical research and the ultimate clearance of three new diagnostic devices by the U.S. Food and Drug Administration (FDA). Dr. Lonky has published numerous articles in the peer-reviewed literature in the area of cellular physiology and its relation to cervical and oral cancer detection. Since Early 2007 he has been a Board Member of Histologix, LLC, a company that is bringing innovative biopsy tools to the medical marketplace. Dr. Lonky is specifically involved with the regulatory clearances of these novel devices for use on various tissue surfaces. Dr. Lonky earned his B.S. degree at St. Lawrence University, his M.D. from the State University of New York, Downstate, and his M.B.A. from Pepperdine University.

   
   
Garry R. Pottruck

Garry R. Pottruck
Director

Garry R. Pottruck, 57 years of age, is currently a Principal in the certified public accounting firm Blum and Blum, located in Coral Springs, Florida, where he has worked since 2011. Prior to this, he worked for Argy, Wiltse & Robinson, a Virginia-based accounting and consulting firm, from 2005 until 2010. From 1997 through 2005, he was managing partner in the certified public accounting firm, Friedberg & Pottruck, PA, located in Deerfield Beach, Florida. Friedberg & Pottruck specialized in providing accounting, tax and consulting services, primarily to physician practices.

Mr. Pottruck held financial executive positions with several companies, both public and private, from 1984 through 1994, including more than three years as Chief Accounting Officer/Controller at Scopas Technology Company, Inc., a NASDAQ listed, development stage biotechnology research and development organization.

Prior to 1984, Mr. Pottruck worked for public accounting firms after graduating with a B.S. Degree in Accounting from the C.W. Post School of Professional Accountancy at Long Island University in 1979. He is currently licensed as a Certified Public Accountant in both Missouri and Florida.

 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
July 24, 2014
Nutra Pharma Announces Infrastructure Improvements to Handle Increased Sales


June 10, 2014
Nutra Pharma Announces Contracts for Nyloxin Television Commercials


January 07, 2014
Nutra Pharma Announces the First Shipments and Product Delivery to MyNyloxin.com Independent Entrepreneurs


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics